Table 1

 Characteristics of cases with bladder cancer diagnosed after diagnosis of Wegener’s granulomatosis in a population based cohort of 1065 patients with Wegener’s granulomatosis in Sweden, 1969–94

Year of birthSexAge at WGAge at cancerTime from WG to cancer (months)Time from CY to cancer* (months)Cumulative dose of CY (g)Duration of CY (months)Bladder cancerSmoking status
WG, Wegener’s granulomatosis; CY, cyclophosphamide.
*Time from stopping CY treatment to appearance of bladder cancer; †this patient continued to receive cyclophosphamide even after the diagnosis of bladder cancer was made—that is, CY was never discontinued.
1915M58669696Non-invasiveNo information
1915M6680168163235Non-invasiveNo information
1910M758310310111598InvasiveNever smoker
1922M6873701417856InvasiveNever smoker
1933M41561802224178InvasiveNever smoker
1900F74784800InvasiveNever smoker
1909F70745115450Non-invasiveNo information
1942F405112531110108Non-invasiveNever smoker